Clinical Trial Update: A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating subcutaneously administered pozelimab with cemdisiran or cemdisiran alone in adults with geographic atrophy due to age-re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• Cemdisiran (cemdisiran)
• Pozelimab

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Age-related Macular Degeneration (AMD), Geographic Atrophy (GA) | Phase 3 | Status: RECRUITING